Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities

•Analysis of rare histology types in endometrial cancer in two different centers.•Real world evidence comparison of survival outcome of different adjuvant modalities.•Shows the importance of Radiotherapy compared to Chemotherapy in the adjuvant setting. Adjuvant treatment for endometrial carcinoma (...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment and research communications Vol. 32; p. 100581
Main Authors: Nogueira-Costa, Gonçalo, Eiriz, Inês, Braga, Sofia
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-01-2022
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Analysis of rare histology types in endometrial cancer in two different centers.•Real world evidence comparison of survival outcome of different adjuvant modalities.•Shows the importance of Radiotherapy compared to Chemotherapy in the adjuvant setting. Adjuvant treatment for endometrial carcinoma (EC) is decided based on risk assessment. Tumors of non-endometrioid (NE) histology are classified as high-risk and adjuvant treatment is recommended. We analyzed retrospectively all NEEC patients treated in two Portuguese oncology centers, between 2009 and 2018. Comparison of adjuvant modalities were performed by overall survival (OS) and disease-free survival (DFS) analysis. A total of 66 patients were included, with mean age 69 years. Serous histology was found in 34 patients (51.5%), clear-cell in 13 (19.7%) and carcinosarcoma in 18 (27.3%). Based on FIGO staging-system, 34 (51.5%) patients were diagnosed at stages III-IV. Following surgery, no further treatment was performed in 16 patients (24.4%), 11 (16.7%) received isolated chemotherapy (CT), 11 (16.7%) isolated radiotherapy (RT) and 28 (42.4%) combination therapy (CT+RT). Kaplan-Meier analysis showed higher median (m)DFS in the CT+RT group: 30.7 months (m) compared to RT alone: 14.1 m. The mDFS of the isolated CT group was 10.8 m and for patients with no further treatment it was 5.7 m, p = 0.03. Median OS was also increased in the combination group CT+RT (78.3 m) compared to isolated RT (64.3 m), isolated CT (37.3 m) and no further treatment (46.7 m), p=0.005. Multivariate Cox-regression using CT+RT as reference, showed hazard-ratio of 3.5 (p = 0.05) and 4.5 (p = 0.01) for the CT and for no-treatment group respectively. In NEEC patients, DFS and OS analysis showed better prognosis in combination of CT+RT. Patients that underwent only RT had better survival outcomes when compared to those treated with CT only.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2468-2942
2468-2942
DOI:10.1016/j.ctarc.2022.100581